Oragenics Stock Price, News & Analysis

Oragenics has appointed Dr. William “Frank” Peacock as Chief Clinical Officer, with a focus on conducting a Phase II clinical trial for ONP-002, a drug aimed at treating concussions in the Emergency Department. Dr. Peacock, a renowned emergency medicine expert, will oversee this trial in collaboration with Avance Clinical. Previous Phase I trials indicated ONP-002 is safe and well-tolerated. The trial aims to assess biomarkers and symptom severity post-concussion. Concussions, affecting 69 million people globally each year, remain a critical unmet medical need. Dr. Peacock's extensive background in emergency medicine and concussion research is expected to be pivotal for the success of this trial.

Oragenics announced a webinar on neurotrauma medicine to be held on May 20, 2024, at 12:00 PM ET. The webinar will focus on Traumatic Brain Injury (TBI), its causes, and its links to long-term neurological disorders. The company will discuss their lead drug candidate, ONP-002, a neurosteroid for mild TBI, and present outcomes from preclinical and Phase I trials. Details of the forthcoming Phase II trial in acute and emergency departments will also be covered. Expert speakers include Dr. James P. Kelly and Dr. Frank Peacock IV.

Oragenics (NYSE American: OGEN) announced preparations for a Phase II clinical trial of its lead drug candidate, ONP-002, designed to treat mild Traumatic Brain Injury (mTBI). The trial will focus on intranasal delivery for rapid brain targeting, bypassing the blood-brain barrier. Oragenics has optimized the drug formulation and secured intranasal devices, partnering with Avance Clinical to implement the trial in emergency departments of level one trauma centers. Preclinical studies showed promising results in brain injury outcomes, and Phase I trials confirmed ONP-002's tolerability in humans. Concussions, a significant global health issue, often lead to long-term neurological disorders, highlighting the need for effective treatments like ONP-002.

Oragenics, Inc. partners with Avance Clinical for a Phase II clinical trial in Australia to evaluate ONP-002 for mild Traumatic Brain Injury (TBI). The partnership aims to address the significant unmet medical need for concussion treatment through innovative intranasal pharmaceuticals. Oragenics' lead drug candidate, ONP-002, has shown promise in a Phase I trial and is delivered through a unique intranasal device designed for direct brain delivery. Avance Clinical's expertise in managing clinical trials in Australia, New Zealand, and North America brings valuable experience to the collaboration, highlighting the potential for future concussion treatment protocols.